Fox Run Management L.L.C. Purchases Shares of 25,422 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Fox Run Management L.L.C. acquired a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,422 shares of the biopharmaceutical company's stock, valued at approximately $466,000.

Other institutional investors have also added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter worth approximately $47,000. Quest Partners LLC lifted its position in shares of ACADIA Pharmaceuticals by 42.3% during the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 1,047 shares during the last quarter. KBC Group NV boosted its stake in shares of ACADIA Pharmaceuticals by 67.0% during the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 2,044 shares during the period. Globeflex Capital L P bought a new position in shares of ACADIA Pharmaceuticals in the fourth quarter worth about $168,000. Finally, Xponance Inc. purchased a new position in ACADIA Pharmaceuticals in the 4th quarter worth about $186,000. Institutional investors own 96.71% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ACAD shares. Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "hold" rating and a $22.00 target price on the stock. HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. StockNews.com upgraded ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, March 8th. Cantor Fitzgerald reissued an "overweight" rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $23.93.

Remove Ads

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,171 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $54,065.55. Following the completion of the transaction, the executive vice president now directly owns 56,889 shares of the company's stock, valued at approximately $969,957.45. This trade represents a 5.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the sale, the director now owns 17,595 shares of the company's stock, valued at approximately $320,756.85. The trade was a 21.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,433 shares of company stock worth $187,319. Company insiders own 28.30% of the company's stock.

ACADIA Pharmaceuticals Stock Performance

ACAD stock traded down $0.12 during trading on Friday, reaching $17.07. The company had a trading volume of 872,276 shares, compared to its average volume of 1,823,322. ACADIA Pharmaceuticals Inc. has a twelve month low of $14.15 and a twelve month high of $20.68. The company has a market cap of $2.85 billion, a price-to-earnings ratio of 21.88 and a beta of 0.43. The firm has a 50-day simple moving average of $18.34 and a 200-day simple moving average of $17.04.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.